Acrivon Therapeutics

Moat assessment is prospective. Intangible assets: moderate. AP3 and drug‑specific OncoSignature diagnostics are proprietary, the ACR‑368 OncoSignature has FDA Breakthrough Device designations (ovarian and endometrial), and the company has established an internal CLIA lab to operate and evolve its diagnostics.

If the diagnostic is ultimately required on‑label, it can act as a gatekeeper. Score: 55. Switching costs: low-to-moderate. Oncologists can switch therapies, but if OncoSignature is embedded in care pathways and reimbursed as a companion diagnostic, frictions increase. Still unproven until marketing authorization.

Score: 30. Network effects: minimal. Data flywheel exists internally, but lacks two‑sided network dynamics. Score: 15. Cost advantages: limited. No obvious manufacturing or scale cost edge pre‑commercialization.

Score: 20. Efficient scale: niche tumor subtypes and a required diagnostic could limit entrant incentives in small indications, but broader markets remain competitive.

Score: 30. Weighted view: potential diagnostic gatekeeping and IP are real but contingent on successful registrational outcomes and regulatory decisions; Lilly license terms show freedom to partner but also future milestone and royalty obligations. Overall moat score: 40.